Rosenthal J, Thurnreiter M, Plaschke M, Geyer M, Reiter W, Dahlheim H
Ulm University Medical Center, FRG.
Hypertension. 1990 Jun;15(6 Pt 2):848-53. doi: 10.1161/01.hyp.15.6.848.
The present study was designed to identify angiotensin I (Ang I)-forming angiotensinogenases in human extrarenal vasculature and to examine the theory of Jiménez Días on their stimulation in essential hypertension. Vascular sections obtained intraoperatively from 14 normotensive and 16 hypertensive patients undergoing corrective surgery, 68 umbilical cord blood vessels from parturient women, tissue samples from nine explanted hearts, and serum from anephric and healthy individuals were investigated. Ang I-forming angiotensinogenase activities were determined enzyme-kinetically by using Ang I radioimmunoassay and purified sheep or human angiotensinogens. Three nonrenin Ang I-forming angiotensinogenases (pH optima of 4.0, 5.1, and 6.1) were identified in extrarenal vasculature, in cardiac tissues, and in plasma. Highest specific activities of nonrenin Ang I-forming angiotensinogenase (in nanograms Ang I per gram times hour; mean +/- SD) were found in cardiac tissue (2,821 +/- 497, n = 9), followed by carotid artery intima (1,448 +/- 982, n = 10), arteries (1,307 +/- 736, n = 18), and umbilical cord arteries (135 +/- 55, n = 35). Extrarenal arterial Ang I-forming angiotensinogenases were linearly correlated with those of local angiotensin converting enzyme and plasma renin activity. In essential hypertension, extrarenal arterial Ang I-forming angiotensinogenases were scattered, but not generally stimulated. The data obtained indicate the existence of nonrenin Ang I-forming angiotensinogenases in human extrarenal vasculature, in kidney, and in plasma. The postulate of stimulation of extrarenal arterial Ang I-forming angiotensinogenases in essential hypertension cannot be supported. Similar to the classification of plasma renin activity, a classification of Ang I-forming angiotensinogenase activity is proposed, consisting of patients with essential hypertension divided into subgroups exhibiting high, normal, or low vascular Ang I-forming angiotensinogenase activities.
本研究旨在鉴定人类肾外血管中生成血管紧张素I(Ang I)的血管紧张素原酶,并检验希门尼斯·迪亚斯关于原发性高血压中其受刺激的理论。研究了术中从14例接受矫正手术的血压正常患者和16例高血压患者获取的血管切片、68例产妇的脐带血管、9个离体心脏的组织样本以及无肾个体和健康个体的血清。通过使用Ang I放射免疫测定法和纯化的绵羊或人血管紧张素原,以酶动力学方法测定生成Ang I的血管紧张素原酶活性。在肾外血管、心脏组织和血浆中鉴定出三种非肾素生成Ang I的血管紧张素原酶(最适pH分别为4.0、5.1和6.1)。非肾素生成Ang I的血管紧张素原酶的最高比活性(以每克每小时生成的Ang I纳克数计;平均值±标准差)在心脏组织中(2,821±497,n = 9),其次是颈动脉内膜(1,448±982,n = 10)、动脉(1,307±736,n = 18)和脐带动脉(135±55,n = 35)。肾外动脉生成Ang I的血管紧张素原酶与局部血管紧张素转换酶和血浆肾素活性呈线性相关。在原发性高血压中,肾外动脉生成Ang I的血管紧张素原酶分布分散,但一般未受刺激。所获得的数据表明在人类肾外血管、肾脏和血浆中存在非肾素生成Ang I的血管紧张素原酶。原发性高血压中肾外动脉生成Ang I的血管紧张素原酶受刺激的假设得不到支持。类似于血浆肾素活性的分类,提出了生成Ang I的血管紧张素原酶活性的分类,即将原发性高血压患者分为血管生成Ang I的血管紧张素原酶活性高、正常或低的亚组。